NCT06234787 Continuous Subcutaneous Glucose Monitoring in Critical Patients
| NCT ID | NCT06234787 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universidad Europea de Madrid |
| Condition | Hyperglycemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 245 participants |
| Start Date | 2023-11-30 |
| Primary Completion | 2027-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 245 participants in total. It began in 2023-11-30 with a primary completion date of 2027-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a single-center, observational, descriptive, longitudinal, and prospective study This study aims to determine the cumulative incidence during admission and the incidence rate of potential hypoglycemic events (defined as subcutaneous glucose \<80 mg/dL detected by CGM) in patients admitted to the Intensive Care Unit (ICU) of HLA Moncloa Hospital over four years of follow-up. The study also aims to document the occurrences of hypoglycemic events, describe the characteristics of patients receiving CGM sensors, and outline the actions taken as a result of detecting potential hypoglycemic events
Eligibility Criteria
Inclusion Criteria: * The study will be conducted in patients admitted to the ICU of HLA Moncloa Hospital over four years. Patients admitted to the ICU, undergoing insulin treatment, and having a CGM sensor. * Patients who sign the voluntary consent to participate in the study (Annex 2). If the participant is not in full physical or intellectual capacity to provide their signature on the informed consent, the responsible investigator will request such consent from their direct family member or the person legally designated to make decisions on their behalf regarding health matters. This measure is taken to ensure that the participant\'s rights are respected, and the integrity of the consent process is maintained, even in situations where their decision-making capacity may be compromised. Exclusion Criteria: * Patients from whom information on CGM cannot be obtained for technical reasons.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06234787 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hyperglycemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06234787 currently recruiting?
Yes, NCT06234787 is actively recruiting participants. Contact the research team at samuelgonlop@gmail.com for enrollment information.
Where is the NCT06234787 trial being conducted?
This trial is being conducted at Madrid, Spain.
Who is sponsoring the NCT06234787 clinical trial?
NCT06234787 is sponsored by Universidad Europea de Madrid. The trial plans to enroll 245 participants.